The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
Váldodahkkit: | Ondondo, B, Ahmed, T, Nicola, B, Hayton, E, Vasilyeva, E, Frahm, N, Colloca, S, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T |
---|---|
Materiálatiipa: | Conference item |
Almmustuhtton: |
2013
|
Geahča maid
-
Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
Dahkki: Borthwick, N, et al.
Almmustuhtton: (2013) -
Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Dahkki: Ondondo, B, et al.
Almmustuhtton: (2013) -
Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
Dahkki: Ondondo, B, et al.
Almmustuhtton: (2013) -
Targeting HIV-1 Where It Hurts
Dahkki: Ahmed, T, et al.
Almmustuhtton: (2013) -
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Dahkki: Hancock, G, et al.
Almmustuhtton: (2017)